The basis and advances in clinical application of boron neutron capture therapy

Boron neutron capture therapy (BNCT) was first proposed as early as 1936, and research on BNCT has progressed relatively slowly but steadily. BNCT is a potentially useful tool for cancer treatment that selectively damages cancer cells while sparing normal tissue. BNCT is based on the nuclear reaction that occurs when B-10 capture low-energy thermal neutrons to yield high-linear energy transfer (LET) alpha particles and recoiling Li-7 nuclei. A large number of B-10 atoms have to be localized within the tumor cells for BNCT to be effective, and an adequate number of thermal neutrons need to be absorbed by the B-10 atoms to generate lethal B-10 (n, alpha)Li-7 reactions. Effective boron neutron capture therapy cannot be achieved without appropriate boron carriers. Improvement in boron delivery and the development of the best dosing paradigms for both boronophenylalanine (BPA) and sodium borocaptate (BSH) are of major importance, yet these still have not been optimized. Here, we present a review of this treatment modality from the perspectives of radiation oncology, biology, and physics. This manuscript provides a brief introduction of the mechanism of cancer-cell-selective killing by BNCT, radiobiological factors, and progress in the development of boron carriers and neutron sources as well as the results of clinical study.

Automated summary

Boron neutron capture therapy (BNCT) is a potentially useful tool for cancer treatment that selectively damages cancer cells while sparing normal tissue. Effective BNCT requires a large number of B-10 atoms to be localized within tumor cells and an adequate number of thermal neutrons to be absorbed for lethal reactions to occur. Improvements in boron delivery and dosing paradigms remain essential for optimizing BNCT effectiveness.